Journal Home
Search for

Volume 35, Issue 9, Pages 1518-1522 (September 2009)


View previous. 11 of 44 View next.

Combined cataract extraction and intravitreal bevacizumab in eyes with choroidal neovascularization resulting from age-related macular degeneration

Claudio Furino, MD, PhD, Andrea Ferrara, MD, Nicola Cardascia, MD, Gianluca Besozzi, MD, Giovanni Alessio, MD, Luigi Sborgia, MD, Francesco Boscia, MDCorresponding Author Informationemail address

Received 18 February 2009; received in revised form 4 April 2009; accepted 8 April 2009.

Purpose

To evaluate the safety and efficacy of phacoemulsification, intraocular lens (IOL) implantation, and a single intravitreal injection of bevacizumab in patients with coexisting visually significant cataract and subfoveal neovascularization due to age-related macular degeneration.

Setting

Department of Ophthalmology, University of Bari, Bari, Italy.

Methods

Eyes with predominantly classic subfoveal neovascularization and cataract had phacoemulsification, IOL implantation, and a 1.25 mg intravitreal injection of bevacizumab. One month after combined surgery, corrected distance visual acuity (CDVA), anterior chamber reaction, and intraocular pressure were evaluated and central foveal thickness was measured by optical coherence tomography.

Results

Twenty eyes of 20 patients were evaluated. One month postoperatively, the mean CDVA improved significantly, from 20/100 (range 20/160 to 20/80) at baseline to 20/63 (range 20/125 to 20/50) (P<.0001). The mean central foveal thickness decreased significantly, from 353.75 μm ± 12.50 (SD) (range 334 to 375 μm) at baseline to 275.7 ± 17.3 μm (range 255 to 323 μm) at 1 month (P<.0001). Intraocular pressure did not change significantly, and anterior chamber reaction was absent. No ocular or systemic adverse events were observed.

Conclusion

Combined phacoemulsification, IOL implantation, and intravitreal bevacizumab was a safe and efficacious treatment in patients with visually significant cataract and active subfoveal neovascularization.

From the Department of Ophthalmology, University of Bari, Bari, Italy

Corresponding Author InformationCorresponding author: Francesco Boscia, MD, Dipartimento di Oftalmologia ed Otorinolaringoiatria, Università di Bari, Piazza Giulio Cesare, 11, 70124 Bari, Italy.

 No author has a financial or proprietary interest in any material or method mentioned.

PII: S0886-3350(09)00560-4

doi:10.1016/j.jcrs.2009.04.032


View previous. 11 of 44 View next.